Please login to the form below

Not currently logged in
Email:
Password:

complementary therapies

This page shows the latest complementary therapies news and features for those working in and with pharma, biotech and healthcare.

Takeda agrees $5.2bn deal to buy Ariad

Takeda agrees $5.2bn deal to buy Ariad

Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this transaction to benefit patients, our shareholders, and other

Latest news

  • UCB launches arthritis exercise programme in the UK

    However, the move comes just as Arthritis Research UK publish a report that criticises many complementary therapies for arthritis as lacking scientific evidence of efficacy. ... Rheumatoid arthritis was singled out in the report as being an area where

  • R&D news in brief

    Last month, a report written by economist Christopher Smallwood and commissioned by the Prince of Wales said that complementary therapies, including herbal medicines, should be used more frequently by the NHS.

  • Doctors attack NHS support of complementary medicine

    It criticised two initiatives - a government-funded guide on homeopathy for patients, and the Smallwood Report, which was commissioned by Prince Charles, and advocates greater access to complementary therapies. ... She said: ìPatients rightly expect to

  • New laws for alternative medicines in UK

    The UK government will regulate aromatherapy, homoeopathy and other complementary therapies in a scheme due later in 2008. ... The NHS spends GBP 50m a year on complementary therapies, which will be covered by the new council.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    disease. Targeting tau. Tau is among the beneficiaries of the broader focus and emerging interest in combination therapies. ... These mechanisms may be complementary. “We think combination therapies between. antibodies and small molecules make a lot of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....